Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Changing Gears - DBS for Dopaminergic Desensitization in Parkinsons Disease?
Ann Neurol 90:699-710, Weiss, D.,et al, 2021
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinsons Disease
NEJM 383:2501-2513,2582, Martinez-Fernandez, R.,et al, 2020
When to Start Levodopa Therapy for Parkinsons Disease
NEJM 380:389-390, Bressman, S. & Saunders-Pullman, R., 2019
The Laser Shoes
Neurol 90:e164-e171, Barthel, C.,et al, 2018
A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Randomized Controlled Clinical Trial of "Virtual House Calls" for Parkinson Disease
JAMA Neurol 70:565-570, Dorsey, E.R.,et al, 2013
Tai Chi and Postural Stability in Patients with Parkinsons Disease
NEJM 366:511-519, Li,F.,et al, 2012
Caffeine for Treatment of Parkinson Disease
Neurol 79:651-658, Postuma, R.B.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation
JAMA 305:732, Pluta,R.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Cycling for Freezing of Gait
NEJM 362:e46, Snijders,A.H., &Bloem,B.R., 2010
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial
JAMA 301:63-73,104, Weaver,F.M.,et al, 2009
Overweight After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Long Term Follow-Up
JNNP 80:484-488, Bannier,S.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease
Neurol 68:272-276, Watts,R.L.,et al, 2007
Advanced Parkinson Disease Treated with Rotigotine Transdermal System PREFER Study
Neurol 68:1262-1267, LeWitt,P.A.,et al, 2007
Improvement of Gait by Chronic, High Doses of Methylphenidate in Patients with Advanced Parkinsons Disease
JNNP 78:470-475, Devos,D.,et al, 2007
Transdermal Rotigotine: Double-Blind, Placebo-Controlled Trial in Parkinson Disease
Arch Neurol 64:676-682, Jankovic,J.,et al, 2007
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006